October 25th 2023
Your daily dose of the clinical news you may have missed.
Nevirapine-based HAART Regimens: What Effect on HIV-Associated Lipodystrophy?
November 20th 2014Long-term highly-active antiretroviral therapy can be associated with disturbing morphologic and metabolic changes. Nevaripine is added to three HAART regimens in this study to evaluate any mitigating effects.
HIV Patients Lack Adequate Control of CVD Risk Factors
September 25th 2014Now that HIV infection is largely a chronic disease, cardiovascular disease has become a leading cause of death in this patient group. Here: a look at just how common LDL-C dyslipidemia, hypertension, and coronary heart disease really are.
Influenza Vaccine Protects HIV-Positive Pregnant Women from Flu Infection
September 24th 2014The flu vaccine effectively prevents influenza in pregnant women, regardless of whether they are HIV positive, according to a new study. Results offer clinicians greater assurance to vaccinate all pregnant woman.
MVC + DRV-r Maintains HIV Suppression in Retreated Patients
September 2nd 2014A once daily MVC plus DRV/r regimen had an effective role in antiretroviral drug-pretreated individuals with controlled HIV infection in this trial. In an aging HIV-infected population, with increasing comorbidities, this combination could be a safer option than standard triple therapy. More here.
Efavirenz for Initial Therapy of HIV Associated with Increased Suicide Risk
August 1st 2014A statistically significant association exists between efavirenz for initial HIV therapy and the risk suicidality. When this drug is given as a component of an antiretroviral drug regimen, patients should be monitored carefully for the possibility of deterioration of their depression or evidence of suicidal behavior.
Antiviral Therapy Use Varies by Gender and Ethnic Groups
July 15th 2014Women of all races and ethnicities are less likely to take antiretroviral therapy than men. Consideration of both gender and race/ethnicity is thus needed to identify areas for targeted intervention to improve outcomes relevant to specific groups of women."